Normally you would think that having a differentiated and proprietary
diabetes compound with solid supporting data would make a biotech
relatively popular. That would often be particularly true in cases where
the drug class has already proven to be pretty popular with drug
companies and started to generate real interest among clinicians.
Unfortunately for Lexicon Pharmaceuticals' (LXRX)
shareholders, things aren't going to plan yet. The company's LX4211
remains the only compound I'm aware of that inhibits both SGLT1 and
SGLT2 (other drugs just address SGLT2) and the data have been good so
far. Yet, another SGLT2 partnership deal has gone off in the space
without including Lexicon - forcing investors to wonder whether a good
partnership deal actually is out there to be had and/or whether the
company will have to contemplate going it alone into Phase III studies.
Please keep reading here:
No News Becoming Bad News For Lexicon Pharmaceuticals
No comments:
Post a Comment